Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study

BACKGROUND: Data on the safety and efficacy profile of tocilizumab in patients with severe COVID-19 needs to be enriched. METHODS: In this open label, prospective study, we evaluated clinical outcomes in consecutive patients with COVID-19 and PaO(2)/FiO(2) < 200 receiving tocilizumab plus usual c...

Descripción completa

Detalles Bibliográficos
Autores principales: Karampitsakos, Theodoros, Malakounidou, Elli, Papaioannou, Ourania, Dimakopoulou, Vasilina, Zarkadi, Eirini, Katsaras, Matthaios, Tsiri, Panagiota, Tsirikos, Georgios, Georgiopoulou, Vasiliki, Oikonomou, Ioanna, Davoulos, Christos, Velissaris, Dimitrios, Sampsonas, Fotios, Marangos, Markos, Akinosoglou, Karolina, Tzouvelekis, Argyris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692825/
https://www.ncbi.nlm.nih.gov/pubmed/34937570
http://dx.doi.org/10.1186/s12931-021-01914-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692825/
https://www.ncbi.nlm.nih.gov/pubmed/34937570
http://dx.doi.org/10.1186/s12931-021-01914-6

Ejemplares similares